CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma.
<h4>Purpose</h4> <p>Although pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor, like other common cancers, it displays a wide range of biology. However, at present, there are no reliable tests to predict patients’ cancer-specific outcomes and guide personalized treatme...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research
2016
|
| _version_ | 1797100724554825728 |
|---|---|
| author | Stracquadanio, G Vrugt, B Flury, R Schraml, P Würl, P Müller, T Knippschild, U Henne-Bruns, D Breitenstein, S Clavien, P Graf, R Bond, G Grochola, L |
| author_facet | Stracquadanio, G Vrugt, B Flury, R Schraml, P Würl, P Müller, T Knippschild, U Henne-Bruns, D Breitenstein, S Clavien, P Graf, R Bond, G Grochola, L |
| author_sort | Stracquadanio, G |
| collection | OXFORD |
| description | <h4>Purpose</h4> <p>Although pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor, like other common cancers, it displays a wide range of biology. However, at present, there are no reliable tests to predict patients’ cancer-specific outcomes and guide personalized treatment decisions. In this study, we aim to identify such biomarkers in resectable PDAC by studying single nucleotide polymorphisms (SNPs) in the CD44 gene, which drives the progression of pancreatic cancer. </p> <h4>Experimental Design</h4> <p>348 PDAC patients from three independent cohorts (Switzerland, Germany, The Cancer Genome Atlas (TCGA)) who underwent pancreatic resection are included in the study. Information on the haplotype structure of the CD44 gene is obtained using 1000 Genomes Projectdata and the genotypes of the respective tagging SNPs are determined. Cox proportional hazards models are utilized to analyze the impact of SNP genotype on patients´ survival. </p> <h4>Results</h4> <p>We identify a SNP in the CD44 gene (SNP rs187115) that independently associates with allelic differences in prognosis in all study cohorts. Specifically, in 121 Swiss patients, we observe an up-to 2.38-fold (p=0.020) difference in tumor-related death between the genotypes of SNP rs187115. We validate those results in both the German (hazard ratio (HR)=2.32, p=0.044, 101 patients) and the TCGA cohort (HR=2.36, p=0.044, 126 patients). </p> <h4>Conclusions</h4> <p> CD44 SNP rs187115 can serve as a novel biomarker readily available at the time of PDAC diagnosis that identifies patients at risk for faster tumor progression and guide personalized treatment decisions. It has the potential to significantly expand the pool of patients that would benefit from tumor resection</p> |
| first_indexed | 2024-03-07T05:41:41Z |
| format | Journal article |
| id | oxford-uuid:e5ca38fe-12cb-4cdb-86a1-f3d5ee2968fd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:41:41Z |
| publishDate | 2016 |
| publisher | American Association for Cancer Research |
| record_format | dspace |
| spelling | oxford-uuid:e5ca38fe-12cb-4cdb-86a1-f3d5ee2968fd2022-03-27T10:26:35ZCD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e5ca38fe-12cb-4cdb-86a1-f3d5ee2968fdEnglishSymplectic Elements at OxfordAmerican Association for Cancer Research2016Stracquadanio, GVrugt, BFlury, RSchraml, PWürl, PMüller, TKnippschild, UHenne-Bruns, DBreitenstein, SClavien, PGraf, RBond, GGrochola, L<h4>Purpose</h4> <p>Although pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor, like other common cancers, it displays a wide range of biology. However, at present, there are no reliable tests to predict patients’ cancer-specific outcomes and guide personalized treatment decisions. In this study, we aim to identify such biomarkers in resectable PDAC by studying single nucleotide polymorphisms (SNPs) in the CD44 gene, which drives the progression of pancreatic cancer. </p> <h4>Experimental Design</h4> <p>348 PDAC patients from three independent cohorts (Switzerland, Germany, The Cancer Genome Atlas (TCGA)) who underwent pancreatic resection are included in the study. Information on the haplotype structure of the CD44 gene is obtained using 1000 Genomes Projectdata and the genotypes of the respective tagging SNPs are determined. Cox proportional hazards models are utilized to analyze the impact of SNP genotype on patients´ survival. </p> <h4>Results</h4> <p>We identify a SNP in the CD44 gene (SNP rs187115) that independently associates with allelic differences in prognosis in all study cohorts. Specifically, in 121 Swiss patients, we observe an up-to 2.38-fold (p=0.020) difference in tumor-related death between the genotypes of SNP rs187115. We validate those results in both the German (hazard ratio (HR)=2.32, p=0.044, 101 patients) and the TCGA cohort (HR=2.36, p=0.044, 126 patients). </p> <h4>Conclusions</h4> <p> CD44 SNP rs187115 can serve as a novel biomarker readily available at the time of PDAC diagnosis that identifies patients at risk for faster tumor progression and guide personalized treatment decisions. It has the potential to significantly expand the pool of patients that would benefit from tumor resection</p> |
| spellingShingle | Stracquadanio, G Vrugt, B Flury, R Schraml, P Würl, P Müller, T Knippschild, U Henne-Bruns, D Breitenstein, S Clavien, P Graf, R Bond, G Grochola, L CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. |
| title | CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. |
| title_full | CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. |
| title_fullStr | CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. |
| title_full_unstemmed | CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. |
| title_short | CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. |
| title_sort | cd44 snp rs187115 a novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma |
| work_keys_str_mv | AT stracquadaniog cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT vrugtb cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT fluryr cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT schramlp cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT wurlp cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT mullert cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT knippschildu cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT hennebrunsd cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT breitensteins cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT clavienp cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT grafr cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT bondg cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma AT grocholal cd44snprs187115anovelbiomarkersignaturethatpredictssurvivalinresectablepancreaticductaladenocarcinoma |